Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03428646 · ClinicalTrials.gov registry record
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
A clinical trial of Dermatitis, Atopic, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- 858
- Enrollment target
- 20
- Study locations
NCT03428646 is a study of Dermatitis, Atopic that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 858 participants, above the 368-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (133% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT03428646, a study of Dermatitis, Atopic, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 858 participants
- Enrollment target
- 20
- Study locations
Study Summary
A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (20)
California
- Regeneron Investigational Site - Fountain Valley
- Regeneron Investigational Site - Laguna Hills
- Regeneron Investigational Site - Loma Linda
- Regeneron Investigational Site - Los Angeles
- Regeneron Investigational Site - Los Angeles
- Regeneron Investigational Site - Manhattan Beach
- Regeneron Investigational Site - Newport Beach
- Regeneron Investigational Site - Oceanside
- Regeneron Investigational Site - Redondo Beach
- Regeneron Investigational Site - Riverside
- Regeneron Investigational Site - Roseville
- Regeneron Investigational Site - San Diego
- Regeneron Investigational Site - Santa Monica
- Regeneron Investigational Site - Thousand Oaks
Florida
- Regeneron Investigational Site - Coral Gables
- Regeneron Investigational Site - Margate
- Regeneron Investigational Site - West Palm Beach
Alabama
- Regeneron Investigational Site - Birmingham
Arizona
- Regeneron Investigational Site - Gilbert
Connecticut
- Regeneron Investigational Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 858 participants |
| Start Date | 2018-04-06 |
| Est. Completion | 2027-03-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03428646
The ClinicalTrials.gov registry entry for NCT03428646 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 858 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 368-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (133% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT03428646 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT03428646 about?
NCT03428646 is a clinical study titled "Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)". A long-term observational registry in patients with atopic dermatitis (AD) initiating treatment with DUPIXENT® (dupilumab)
What is the current status of trial NCT03428646?
This trial is currently active not recruiting. The enrollment target is 858 participants. The study started on 2018-04-06. Estimated completion is 2027-03-30.
What conditions does trial NCT03428646 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT03428646?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03428646?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03428646 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.